Novo Nordisk A/S (NYSE:NVO) Holdings Trimmed by WealthBridge Capital Management LLC

WealthBridge Capital Management LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 21.8% during the 4th quarter, HoldingsChannel reports. The firm owned 5,301 shares of the company’s stock after selling 1,479 shares during the quarter. WealthBridge Capital Management LLC’s holdings in Novo Nordisk A/S were worth $456,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. International Assets Investment Management LLC grew its position in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. Mediolanum International Funds Ltd purchased a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $98,765,000. DAVENPORT & Co LLC grew its position in Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after purchasing an additional 451,641 shares in the last quarter. Wellington Management Group LLP purchased a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $42,017,000. Finally, DSM Capital Partners LLC grew its position in Novo Nordisk A/S by 16.7% during the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock worth $172,678,000 after purchasing an additional 286,912 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on NVO shares. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Up 1.3 %

Shares of NYSE:NVO opened at $83.38 on Thursday. The stock has a market capitalization of $374.18 billion, a PE ratio of 25.34, a P/E/G ratio of 0.84 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The firm has a fifty day moving average price of $86.89 and a 200 day moving average price of $108.66. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is currently 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.